ArticleScience translational medicine2018

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

Otto Kauko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.